The objective of this double-blind randomised controlled trial was to compare propranolol (in the maintenance dose of 160 mg/day) and topiramate (in the maintenance dose of 100 mg/day) in terms of tolerability and efficacy in preventing chronic migraine over 24 weeks. This study, which was completed by 95 patients with chronic migraine, showed that there was no statistically significant difference between the two treatments in the primary as well as in the multiple secondary outcomes assessing their efficacy in preventing chronic migraine. Moreover, propranolol and topiramate showed a comparable tolerability profile.
Chowdhury D, Bansal L, Duggal A, et al. TOP-PRO study: A randomized double-blind controlled trial of topiramate versus propranolol for prevention of chronic migraine. Cephalalgia. 2021 Sep 27. Online ahead of print. doi: https://doi.org/10.1177/03331024211047454
